PRAX — Praxis Precision Medicines, Inc.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1689548 ·
Last close
$305.06
Market Cap
$8.53B
52W High
$392.70
52W Low
$160.11
ADV30
533,081
Next earnings
2026-11-09
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance in the United States. The company's platforms include Cerebrum, a small molecule platform for CNS small molecule therapies to develop orally available precision therapies; and Solidus to discover and develop antisense oligonucleotide. It also develops ulixacaltamide, a small molecule inhibitor of T-type calcium channels that in NDA for the treatment of essential tremor; relutrigine, a small molecule, which is in NDA for the treatment of SCN2A- and SCN8A-developmental and epileptic encephalopathies (DEE), as well as in Phase 3 trial for broad DEEs; vormatrigine, a small molecule targeting the hyperexcitable state of sodium-channels in the brain that is in Phase 3 trial for the treatment of adjunctive focal epilepsy, as well as in Phase 2 trial for monotherapy focal epilepsy; and Elsunersen, a clinical-stage ASO designed to selectively decrease SCN2A gene expression, which is in Phase 3 trial for the treatment of SCN2A-DEE. In addition, the company is developing product candidates in pre-clinical trial comprising PRAX-020 to treat KCNT1; PRAX-080 that targets PCDH19 mosaic expression disorders; PRAX-090 for targeting SYNGAP1 loss-of-function; and PRAX-100 that targets SCN2A LoF mutations. It has a cooperation and license agreement with RogCon Inc.; research collaboration, option, and license agreement with Ionis Pharmaceuticals, Inc.; and research collaboration and license agreement to develop an iontophoretic transdermal patch for the delivery of ulixacaltamide. The company was formerly known as EpiPM Therapeutics, Inc. and changed its name to Praxis Precision Medicines, Inc. in October 2016. Praxis Precision Medicines, Inc. was incorporated in 2015 and is headquartered in Boston, Massachusetts.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 — — — — — — —
Jun 2026 0 — -96,904,000 -83,720,000 1,390,102,000 474,761,000 49,058,000
Mar 2026 0 — -105,860,000 -92,561,000 1,460,202,000 536,333,000 50,241,000
Dec 2025 0 — -97,044,000 -88,911,000 937,907,000 357,329,000 59,771,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-321,757,000
Investing CF
$-693,785,000
Financing CF
$1,227,450,000
CapEx
$-1,859,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-12.80
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-1,410,523,000
Inventory
—
Receivables
—
ST Investments
$383,472,000
EBIT TTM
$-406,722,000
Pretax Income TTM
$-359,426,000
Interest Exp TTM
—
Analysts
20

Annual Trend (SEC EDGAR, last 5y)

Revenues vs Net Income (last 5y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 0 -326,198,000 -303,268,000 937,907,000 59,771,000 878,136,000 -249,068,000
Dec 2024 8,553,000 -200,165,000 -182,819,000 483,110,000 37,660,000 445,450,000 -131,757,000
Dec 2023 2,447,000 -126,373,000 -123,277,000 87,948,000 18,279,000 69,669,000 -111,136,000
Dec 2022 0 -214,986,000 -214,029,000 115,128,000 39,022,000 76,106,000 -185,043,000
Dec 2021 — — — — — — —

TTM Snapshot

Revenues TTM
$0
NetIncome TTM
$-339,126,000
OpCashFlow TTM
—
Assets (Latest)
$1,390,102,000
Forward EPS
$-9.79

Max Pain — expiry 2028-01-21 (volume-derived — Yahoo OI feed degraded)

max pain strike: $260.00 · spot: $305.19 · call volume: 70 · put volume: 581
Expected Move to 2028-01-21: ±$158.84 (52.05%) — implied range $146.35 – $464.03 · ATM straddle on $310.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
SMMT Summit Therapeutics Inc. $8.53B $10.67 —
SYRE Spyre Therapeutics, Inc. $8.91B $93.81 —
RYTM RHYTHM PHARMACEUTICALS, INC. $8.08B $116.61 —
PTGX Protagonist Therapeutics, Inc $8.07B $124.67 —
TGTX TG THERAPEUTICS, INC. $9.48B $62.71 —

News headlines (Yahoo Finance, 1h cache)

Praxis Precision Medicines Details Launch Readiness for Relutrigine and Ulixacaltamide and Outlines Expanded Pipeline in Preparation to be the Preeminent CNS Biotech at Investor Day
2026-11-12 21:30 · Yahoo
Guggenheim highlights top biotechnology stock
2026-11-12 19:43 · Yahoo
Praxis Precision Medicines (PRAX) Stock Looks Rich Against Its Book Value
2026-11-10 00:16 · Yahoo
Praxis Precision Medicines Provides Corporate Update and Reports Third Quarter 2026 Financial Results
2026-11-09 12:00 · Yahoo
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-11-04 21:01 · Yahoo
Is Investor Day Plans Altering The Investment Case For Praxis Precision Medicines (PRAX)?
2026-10-28 13:10 · Yahoo
Praxis Precision Medicines Announces Third Quarter 2026 Financial Results Date, Investor Day and November Conference Participation
2026-10-27 20:01 · Yahoo
Is Praxis Precision Medicines (PRAX) Priced Too Highly On Book Value?
2026-10-18 21:12 · Yahoo
Praxis (PRAX) Q2 2026 Earnings Call Transcript
2026-08-13 16:29 · Yahoo
Is Praxis (PRAX) Trading Bigger Losses for Long-Run CNS Ambition With Its Cash War Chest?
2026-08-08 22:12 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.